Inhibrx Biosciences, Inc.
INBX
$89.47
$0.370.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 22.79% | 31.40% | 19.62% | -101.54% | 44.97% |
| Total Depreciation and Amortization | -20.44% | -18.14% | -23.29% | 38.87% | 87.50% |
| Total Amortization of Deferred Charges | 37.34% | -- | -- | -23.94% | -57.09% |
| Total Other Non-Cash Items | 8.74% | -6.69% | 4.94% | 100.16% | -57.97% |
| Change in Net Operating Assets | -370.46% | -42,975.00% | -136.57% | -116.34% | -53.81% |
| Cash from Operations | -5.94% | 31.10% | -11.70% | 47.78% | 43.07% |
| Capital Expenditure | -- | 100.00% | 95.95% | 100.00% | 98.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 97.17% | 100.00% | 98.12% |
| Total Debt Issued | -24.98% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -24.42% | -- | -- | -100.00% | 157.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.44% | 33.99% | -9.67% | -16.90% | 351.26% |